Novo Nordisk's combination therapy CagriSema — pairing the amylin analogue cagrilintide with semaglutide — drew a wave of analyst upgrades and revised price targets on Wednesday after the company's Phase 3 REIMAGINE diabetes trial data, released late Tuesday, showed statistically significant improvements in both HbA1c reduction and body weight loss versus semaglutide alone. Several major investment banks, including JPMorgan and Jefferies, issued updated notes raising their 12-month targets on Novo Nordisk ADRs, citing the data as a potential inflection point for the company following earlier disappointments in the obesity indication.
The REIMAGINE trial programme, which enrolled thousands of patients with type 2 diabetes across multiple global sites, demonstrated that CagriSema achieved superior glycaemic control compared to the semaglutide monotherapy arm, with a mean HbA1c reduction exceeding 2.2 percentage points from baseline. Endocrinologists attending the American Diabetes Association's 2026 Scientific Sessions in Chicago, which runs through Wednesday, immediately flagged the data as potentially practice-changing for patients who plateau on GLP-1 monotherapy.
Dr. John Buse of the University of North Carolina, a leading voice at the ADA meeting, told reporters that the dual-mechanism approach 'addresses an unmet need for patients whose diabetes management remains suboptimal on existing GLP-1 receptor agonist regimens.' He noted that the tolerability profile in REIMAGINE appeared manageable, with nausea rates broadly comparable to semaglutide alone — a critical commercial consideration after rival programmes faced dropout concerns.
Novo Nordisk's chief medical officer confirmed Wednesday that the company plans to submit a supplemental regulatory filing to the U.S. Food and Drug Administration for a diabetes indication before year-end 2026, using the full REIMAGINE dataset. The company also indicated it would pursue filings with the European Medicines Agency on a parallel track. Analysts at Morgan Stanley estimated that a successful diabetes label for CagriSema could add between $4 billion and $6 billion in peak annual sales to Novo Nordisk's existing GLP-1 franchise.
The development also intensifies competitive pressure on Eli Lilly, whose own tirzepatide franchise — marketed as Mounjaro for diabetes and Zepbound for obesity — has dominated recent commercial gains. Lilly's stock dipped modestly in early Wednesday trading as investors weighed whether CagriSema's data represented a credible long-term rival. Healthcare sector analysts noted that both companies now possess differentiated combination-approach assets, suggesting the next phase of competition in metabolic disease will centre on tolerability, dosing convenience, and payer access rather than efficacy alone.